View Item 

Show simple item record

Adverse events in HEAAL: when to hold and when to fold

dc.contributor.authorPitt, Bertramen_US
dc.date.accessioned2014-03-05T18:19:12Z
dc.date.available2014-03-05T18:19:12Z
dc.date.issued2012-12en_US
dc.identifier.citationPitt, Bertram (2012). "Adverse events in HEAAL: when to hold and when to fold." European Journal of Heart Failure 14(12): 1319-1321. <http://hdl.handle.net/2027.42/106139>en_US
dc.identifier.issn1388-9842en_US
dc.identifier.issn1879-0844en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106139
dc.publisherWiley Periodicals, Inc.en_US
dc.titleAdverse events in HEAAL: when to hold and when to folden_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelCardiovascular Medicineen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23159580en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106139/1/ejhfhfs167.pdf
dc.identifier.doi10.1093/eurjhf/hfs167en_US
dc.identifier.sourceEuropean Journal of Heart Failureen_US
dc.identifier.citedreferenceKonstam MA Neaton JD Dickstein K Drexler H Komajda M Martinez FA Riegger GA Malbecq W Smith RD Guptha S Poole‐Wilson PA Effects of high‐dose versus low‐dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized double‐blind trial Lancet 2009 374 1840 1848en_US
dc.identifier.citedreferencePitt B Poole‐Wilson PA Segal R Martinez FA Dickstein K Camm AJ Konstam MA Riegger G Klinger GH Neaton J Sharma D Thiyagarajan B Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II Lancet 2000 355 1582 1587en_US
dc.identifier.citedreferenceKierman MS Wentworth D Francis G Martinez FA Dickstein K Komajda M Zannad F Neaton JD Konstam M Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial Eur J Heart Fail 2012 14 1401 1409en_US
dc.identifier.citedreferenceAlbert NM Yancy CW Liang L Zhao X Hernandez AF Peterson ED Cannon CP Fonarow GC Use of aldosterone antagonists in heart failure JAMA 2009 302 1658 1665en_US
dc.identifier.citedreferencePiit B McMurray J Krum H van Veldhuisen DJ Swedberg K Pocock S Zannad F The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure: an analysis of the ‘high‐risk subgroups’. Presented at the ESC Hotline Session 29 August 2011 Parisen_US
dc.identifier.citedreferenceAuthors /Task Force Members McMurray JJ Adamopoulos S Anker SD Auricchio A Böhm M Dickstein K Falk V Filippatos G Fonseca C Sanchez MA Jaarsma T Køber L Lip GY Maggioni AP Parkhomenko A Pieske BM Popescu BA Rønnevik PK Rutten FH Schwitter J Seferovic P Stepinska J Trindade PT Voors AA Zannad F Zeiher A Bax JJ Baumgartner H Ceconi C Dean V Deaton C Fagard R Funck‐Brentano C Hasdai D Hoes A Kirchhof P Knuuti J Kolh P McDonagh T Moulin C Popescu BA Reiner Z Sechtem U Sirnes PA Tendera M Torbicki A Vahanian A Windecker S; Document Reviewers McDonagh T Sechtem U Bonet LA Avraamides P Ben Lamin HA Brignole M Coca A Cowburn P Dargie H Elliott P Flachskampf FA Guida GF Hardman S Iung B Merkely B Mueller C Nanas JN Nielsen OW Orn S Parissis JT Ponikowski P ESC Committee for Practice Guidelines (CPG) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 2012 14 803 869 2012en_US
dc.identifier.citedreferenceButler J Ezekowitz JA Collins SP Givertz MM Teerlink JR Walsh MN Albert NM Westlake Canary CA Carson PE Colvin‐Adams M Fang JC Hernandez AF Hershberger RE Katz SD Rogers JG Spertus JA Stevenson WG Sweitzer NK Tang WH Stough WG Starling RC Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guideline Committee J Card Fail 2012 18 265 281en_US
dc.identifier.citedreferenceVardenay O Wu D‐H Claggett B Desai A Rossignol P Zannad F Pitt B Solomon SC Incidence, predictors and outcomes related to hypo‐ and hyperkalemia in severe heart failure patients treated with an aldosterone blocker J Card Fail 2012 18 S81en_US
dc.identifier.citedreferenceMontague BT Ouellette JR Buller GK Retrospective review of the frequency of ECG changes in hyperkalemia Clin J Am Soc Nephrol 2008 3 324 330en_US
dc.identifier.citedreferenceBoyd DW Red‐blood cell potassium and aldosteronism Lancet 1970 295 594 595en_US
dc.identifier.citedreferenceMak G Murphy NH Ali A Walsh A O'Loughlin C Conlon C McCaffrey D Ledwidge M McDonald K Multiple neurohumeral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? J Card Fail 2008 14 555 560en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhfhfs167.pdf
Size:
71.94KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.